NEW YORK (GenomeWeb) – Myriad Genetics said on Tuesday that it has completed its acquisition of reproductive genetic testing firm Counsyl.

The move, which Myriad announced in May, will allow Myriad to expand into carrier screening with Counsyl's Foresight test, which covers more than 175 clinically actionable conditions across ethnicities, and into the rapidly growing noninvasive prenatal screening market with Counsyl's Prelude test.